[News] Bosutinib more effective than imatinib in CML

Bosutinib might be a more effective first-line therapy than imatinib for patients with newly diagnosed chronic myeloid leukaemia (CML), according to results from the randomised, phase 3 BFORE trial.

Source: The Lancet Oncology - November 9, 2017 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research